QT IMAGING HOLDINGS, INC. 8K

QT Imaging Holdings, Inc. issued a mid‑year 2026 shareholder letter detailing strong revenue growth, capital raising and debt extension, regulatory and clinical milestones, manufacturing expansion, and strategic priorities to drive broader adoption of its Breast Acoustic CT imaging platform.

On August 18, 2026, QT Imaging Holdings, Inc. issued a mid‑year 2026 shareholder letter in which CEO Dr. Raluca Dinu reviewed the company’s operational and financial progress, including generating $14.0 million in first‑half 2026 revenue (up 116% year over year) from shipping 28 Breast Acoustic CT scanners, reiterating full‑year 2026 revenue guidance of approximately $39 million, and highlighting expanded commercial infrastructure and distribution partnerships in the U.S., Gulf region and Pakistan. The letter described key balance sheet and capital markets actions, including completion of a $10 million underwritten public offering, extension of the senior secured term loan maturity to March 31, 2029, the company’s relisting on the Nasdaq Capital Market, and inclusion in the Russell Microcap Index, leaving QT Imaging with approximately $14.2 million in cash and restricted cash as of August 7, 2026. Management also reported multiple regulatory and quality milestones—two new FDA clearances for enhancements to the Breast Acoustic CT system, regulatory authorizations in Saudi Arabia, the United Arab Emirates and Israel, and completion of the company’s first routine FDA inspection with zero Form 483 observations—along with clinical and reimbursement progress, including ongoing and planned clinical studies at Mayo Clinic, Sunnybrook, Rambam Health Care Campus and others, and the American Medical Association’s approval of a Category III CPT code for 3D quantitative transmission volumetric ultrasound tomography of the breast, effective January 1, 2027. The letter further outlined investments in innovation (including collaborations with Olea Medical and Intelerad and development of AI‑enabled tools), leadership additions such as the appointment of Dr. Julia Albright as Chief Science Officer, expansion of manufacturing capacity via relocation to a 22,000‑square‑foot Petaluma, California facility with lower lease costs, and the company’s strategic priorities for the remainder of 2026 focused on accelerating adoption, strengthening clinical and scientific evidence, expanding global market access, advancing its imaging platform, and scaling operations.

Filing Facts

CIK

1844505

Ticker

-

Form

8K

Source Type

sec

Accession

0001628280-26-057548

Alert Tier

6